Journal of Applied Physiology, Vol 72, Issue 1 179-185, Copyright © 1992 by American Physiological Society

ARTICLES

Dextran sulfate and heparin sulfate inhibit platelet-activating factor-induced pulmonary edema

D. Hocking, T. J. Ferro and A. Johnson
Research Service, Veterans Affairs Medical Center, Albany, New York.

We tested the hypothesis that dextran sulfate and heparin sulfate inhibit platelet-activating factor- (PAF) induced pulmonary edema in the isolated perfused guinea pig lung via a charge-dependent mechanism. Dextran sulfate prevented the changes in pulmonary capillary pressure (Ppc, 7.8 +/- 0.9 vs. 14.0 +/- 0.7 cmH2O), lung weight gain (dW, +0.48 +/- 0.29 vs. +8.41 +/- 2.07 g), and pulmonary edema formation or wet-to-dry weight ratio [(W-D)/D, 6.5 +/- 0.3 vs. 13.2 +/- 2.6] occurring 60 min after PAF infusion (10(-11) M) into an isolated lung. The unsulfated form of dextran had no protective effect [Ppc, dW, and (W-D)/D, 11.9 +/- 1.4 cmH2O, +5.33 +/- 2.18 g, and 11.2 +/- 3.2, respectively]. The unrelated anionic compound, heparin sulfate, also inhibited the PAF response [Ppc, dW, and (W-D)/D, 7.0 +/- 0.5 cmH2O, +0.61 +/- 0.32 g, and 6.1 +/- 0.2, respectively], whereas the partially desulfated form of heparin was not effective in inhibiting PAF-induced edema [Ppc, dW, and (W-D)/D, 15.1 +/- 0.7 cmH2O, +6.07 +/- 1.58 g, and 10.0 +/- 1.2, respectively]. When the metachromatic dye crystal violet was used as an indicator of charge interactions, the sulfated compounds interacted with PAF in vitro. The data indicate that PAF-induced pulmonary edema is inhibited by sulfated polysaccharides, possibly via a charge interaction between negatively charged compounds and PAF.

This article has been cited by other articles:

				R. Goggel and S. Uhlig The inositol trisphosphate pathway mediates platelet-activating-factor-induced pulmonary oedema Eur. Respir. J., May 1, 2005; 25(5): 849 - 857. [Abstract] [Full Text] [PDF]

				C. Martin, R. Goggel, A.-R. Ressmeyer, and S. Uhlig Pressor responses to platelet-activating factor and thromboxane are mediated by Rho-kinase Am J Physiol Lung Cell Mol Physiol, July 1, 2004; 287(1): L250 - L257. [Abstract] [Full Text] [PDF]

				A Salas, M Sans, A Soriano, J C Reverter, D C Anderson, J M Pique, and J Panes Heparin attenuates TNF-alpha induced inflammatory response through a CD11b dependent mechanism Gut, July 1, 2000; 47(1): 88 - 96. [Abstract] [Full Text] [PDF]

				S. FALK, R. GÖGGEL, U. HEYDASCH, F. BRASCH, K.-M. MÜLLER, A. WENDEL, and S. UHLIG Quinolines Attenuate PAF-induced Pulmonary Pressor Responses and Edema Formation Am. J. Respir. Crit. Care Med., November 1, 1999; 160(5): 1734 - 1742. [Abstract] [Full Text]

				A. Fryer, Y.-C. Huang, G. Rao, D. Jacoby, E. Mancilla, R. Whorton, C. A. Piantadosi, T. Kennedy, and J. Hoidal Selective O-Desulfation Produces Nonanticoagulant Heparin that Retains Pharmacological Activity in the Lung, J. Pharmacol. Exp. Ther., July 1, 1997; 282(1): 208 - 219. [Abstract] [Full Text]

				H. Engelberg State-of the-Art Review : Endogenous Heparin Activity Deficiency and Atherosclerosis Clinical and Applied Thrombosis/Hemostasis, April 1, 1996; 2(2): 83 - 93. [PDF]